- Pharmaron’s net income for the first quarter is 305.6 million yuan.
- The company’s revenue for the same period amounts to 3.10 billion yuan.
- Analyst recommendations include 15 buy ratings.
- There are 3 hold ratings from analysts.
- Analysts issued 2 sell ratings.
A look at Pharmaron Beijing Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Pharmaron Beijing Co., Ltd. shows promising signs for its long-term prospects based on the Smartkarma Smart Scores. With solid ratings in Growth and Resilience, scoring 4 out of 5 on both factors, the company demonstrates a strong potential for expansion and the ability to withstand market challenges. This suggests a positive outlook for Pharmaron Beijing’s future strategic developments and sustained performance.
Furthermore, Pharmaron Beijing received respectable scores of 3 out of 5 in Value, Dividend, and Momentum categories. While these scores indicate room for improvement in areas such as value and momentum, the overall balanced performance across different factors bodes well for the company’s overall stability and growth trajectory in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
